NCT04151563 2023-12-19
CheckMate 79X
Bristol-Myers Squibb
Phase 1/2 Withdrawn
Bristol-Myers Squibb
NextCure, Inc.
University of Kentucky
University of Miami
Yonsei University
Ohio State University Comprehensive Cancer Center
University of Southern California